Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring

Fred Saad, Cora N. Sternberg, Eleni Efstathiou, Karim Fizazi, Katharina Modelska, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Neal D. Shore, Maha Hussain

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

While the majority of enzalutamide-treated patients with nonmetastatic castration-resistant prostate cancer in PROSPER had some increase from nadir in prostate-specific antigen at the time of radiographic progression, the median absolute increase was less than the Prostate Cancer Working Group 2 threshold of 2 ng/mL.

Original languageEnglish
Pages (from-to)847-853
Number of pages7
JournalEuropean Urology
Volume78
Issue number6
DOIs
Publication statusPublished - 1 Dec 2020
Externally publishedYes

Keywords

  • Enzalutamide
  • Nonmetastatic castration-resistant prostate cancer
  • Prostate Cancer Working Group 2
  • Prostate-specific antigen progression

Cite this